Skip to main content
Jonathan Strosberg, MD, Oncology, Tampa, FL, H. Lee Moffitt Cancer Center and Research Institute

JonathanRStrosbergMD

Oncology • Tampa, FL

Assistant Professor, Oncologic Sciences, USF-Morsani

Request Appointment

Overview of Dr. Strosberg

Dr. Jonathan Strosberg is an oncologist in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute and Tampa General Hospital. He received his medical degree from Weill Cornell Medicine and has been in practice 18 years. Dr. Strosberg accepts several types of health insurance, listed below. He is one of 171 doctors at H. Lee Moffitt Cancer Center and Research Institute and one of 66 doctors at Tampa General Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • University of South Florida Morsani
    University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2003 - 2006
  • MedStar Health/Georgetown University Hospital
    MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1999 - 2002
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 1999

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2003 - 2025
  • MT State Medical License
    MT State Medical License 2003 - 2004
  • DC State Medical License
    DC State Medical License 2002 - 2004
  • VA State Medical License
    VA State Medical License 2000 - 2004

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut neuroendocrine tumors. 
    2019 ASCO Annual Meeting - 6/1/2019
  • First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high ... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
  • Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
  • Join now to see all

Other

Press Mentions

  • 'Clinically Meaningful' Survival Gain in Neuroendocrine Tumors
    'Clinically Meaningful' Survival Gain in Neuroendocrine TumorsJuly 1st, 2021
  • Strosberg Discusses Lutathera Approval, Remaining Challenges in NETs
    Strosberg Discusses Lutathera Approval, Remaining Challenges in NETsFebruary 28th, 2018
  • New Treatment for Certain Digestive Tract Cancers
    New Treatment for Certain Digestive Tract CancersFebruary 20th, 2018
  • Join now to see all

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    Anthem Blue Access Choice PPO
    Anthem Blue Access PPO
    Anthem Blue Preferred HMO
    Anthem Blue Preferred Plus POS
    Anthem Blue Preferred Select
    AvMed Health Open Access
    BCBS Blue Card PPO
    BCBS Florida BlueCare HMO
    BCBS Florida NetworkBlue
    BCBS Florida Preferred Patient Care PPO
    BCBS Illinois PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Coventry Florida - Employer Group PPO
    Coventry Health Care PPO Platinum
    Coventry Missouri - HMO/POS
    First Health PPO
    Great West PPO
    HealthLink PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. Jonathan Strosberg, Dr. Jonathan Strosberg, MD, Dr. J Strosberg, Dr. Jonathan R Strosberg